Crohn's Disease Therapeutics Market To Reach $16.28 Billion By 2030

Crohn's Disease Therapeutics Market Growth & Trends

The global crohn's disease therapeutics market size is expected to reach USD 16.28 billion in 2030 and is projected to grow at a CAGR of 2.7% from 2024 to 2030. Increasing awareness of the disease, coupled with rising initiatives by regulatory bodies for development of novel treatment options, is estimated to provide the market with high growth potential.

For instance, the American Gastroenterological Association (AGA), in collaboration with Pfizer, supports research projects related to inflammatory bowel diseases and has offered three grants in their name. The Crohn’s & Colitis Foundation, European Federation of Crohn’s & Ulcerative Colitis Associations, and American Autoimmune Related Diseases Association are some of the organizations providing funds for research.

Furthermore, increase in prevalence of Crohn’s disease has directed many companies to collaborate with various regulatory bodies and research institutes to introduce novel and effective treatment for the condition. In 2016, Pfizer’s Centers for Therapeutic Innovation (CTI) collaborated with Johns Hopkins University to discover new medicines to treat Crohn’s disease and ulcerative colitis.

 Request a free sample copy or view report summary: Crohn’s Disease Therapeutics Market Report

Crohn's Disease Therapeutics Market Report Highlights

• Non-surgical dominated the market and accounted for a share of 70.3% in 2023 owing to the advancements in medication and the development of powerful biological therapies and biosimilars  that effectively manage Crohn's disease

• North America crohn’s disease therapeutics dominated the market in 60.25% of the global revenue in 2023. High incidences of Chron’s in patients are one of the major growth drivers

• Some of the key players in the market are Johnson & Johnson Services Inc.; Pfizer Inc.; Allergan; and AbbVie Inc.

Crohn's Disease Therapeutics Market Segmentation

Grand View Research has segmented the global crohn's disease therapeutics market report based on type, route of administration, distribution channel, and region:

Crohn's Disease Therapeutics Type Outlook (Revenue, USD Million, 2018 - 2030)

• Non-Surgical

  • Anti-Inflammatory

  • Immune system suppressors

  • Antibiotics

  • Others

• Surgical

Crohn's Disease Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Injectable

• Oral

Crohn's Disease Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Crohn's Disease Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Crohn's Disease Therapeutics Market

• Takeda Pharmaceutical Company Limited

• AbbVie Inc.

• Perrigo Company plc

• Pfizer Inc.

• Johnson & Johnson Services Inc.

• Ferring B.V.

• Bristol-Myers Squibb Company (Celgene Corporation)

• F. Hoffmann-La Roche Ltd (Genentech, Inc.)

• UCB S.A.

• Salix Pharmaceuticals

• Gilead Sciences Inc.